EP Patent

EP0364417A1 — Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

Assigned to Pfizer Health AB · Expires 1990-04-18 · 36y expired

What this patent protects

The invention relates to ophthalmological compositions for topical treatment of glaucoma or ocular hypertension com­prising an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring struc…

USPTO Abstract

The invention relates to ophthalmological compositions for topical treatment of glaucoma or ocular hypertension com­prising an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring structure, in an ophthalmologically compatible carrier. The invention further relates to the preparation of said compositions and their use for treatment of glaucoma or ocular hypertension.

Drugs covered by this patent

Patent Metadata

Patent number
EP0364417A1
Jurisdiction
EP
Classification
—
Expires
1990-04-18
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Health AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.